Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study…
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
Business Activity Index at 58.2%; New Orders Index at 54.2%; Employment Index at 51.4%; Supplier Deliveries Index at 52.5% TEMPE,…
Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended…
SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral…
SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology…
Study reveals that 5'-tRNAGly(GCC) is a key regulator of gene expression and a potential therapeutic target in cancer SEOUL, Dec.…
Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing…
FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…
Business Activity Index at 53.7%; New Orders Index at 53.7%; Employment Index at 51.5%; Supplier Deliveries Index at 49.5% TEMPE, Ariz., Dec.…
